Connect Biopharma Holdings Limited
Key Metrics
- Previous Close
- $0.58
- 52-Week Range
- $0.55 ā $3.82
- Market Cap
- $42.90M
- P/E (TTM)
- ā
- EPS (TTM)
- -1.35
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.48
- PEG Ratio
- ā
- Return on Equity
- -201.53%
- Return on Assets
- -90.73%
- Gross Margin
- 100.00%
- Operating Margin
- -1879.91%
- Profit Margin
- 0.00%
- Current Ratio
- 1.49
- Debt/Equity
- 0.04
- Total Debt
- $496.00K
- Free Cash Flow
- $-29.68M
- Revenue Growth
- 4500.00%
- Earnings Growth
- ā
- Enterprise Value
- $23.90M
Market Snapshot
About
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and immunologic diseases. Headquartered in San Diego, California, with research facilities in Suzhou, China, the company leverages its expertise in T cell biology and immune modulation. Connect Biopharma's lead product candidate, CBP-201, is an anti-IL-4Rα antibody being developed for atopic dermatitis and other allergic inflammatory conditions. The company has additional programs targeting various immune-mediated diseases using its proprietary technology platforms. Connect Biopharma utilizes a dual-geography strategy, conducting clinical development in both China and the United States to accelerate timelines and access diverse patient populations.